132nok
-3,1 %
Date:2025-10-28Time:16:18:08Latest report:Q4-2020List:Oslo GrowthTicker:ONCIN
Market Cap:129 mnokEnterprise Value:129 mnokNet Sales:- mnokEarnings:- mnokEmployees:0ISIN:NO0010779341

Ratios

10-year key figure history for Oncoinvent turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Oncoinvent with index and moving average MA50 and MA200.

Stockprice:1,32
MA50:1,44
MA200:1,79
Price/MA200:-26,1 %
RSI (14):44,5
Price/MA50:-8,4 %

Description

Oncoinvent is a clinical phase radiopharmaceutical company developing treatments for solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides to deliver radiation directly to cancer cells. The Company's product candidate, Radspherin®, is an alpha radiation therapy candidate designed for the local treatment of cancer that has spread to body cavities. Oncoinvent has its headquarters in Oslo.

Medical Equipment